GlassScriptPhysician profile
Sharon D Fellingham
NPI 1811965973
$2,575.30
in general payments reported to CMS, 2019-2025
23 companies · $54.93 in 2025
The $54.93 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,055 · 2022: $464 · 2023: $486 · 2024: $515 · 2025: $54.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.09 |
| Education | $112.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $819.48 | 2021 | |
| Novo Nordisk INC | $473.00 | 2021-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $139.26 | 2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $138.42 | 2021-2024 | Mounjaro |
| Abbvie INC. | $131.82 | 2021-2024 | |
| Lundbeck LLC | $103.59 | 2021-2025 | Rexulti |
| Pfizer INC. | $98.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.79 | 2022-2024 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $89.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.10 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $61.27 | 2023-2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $54.17 | 2022-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $53.20 | 2021-2023 | Rexulti |
| Amgen INC. | $45.16 | 2024-2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $38.20 | 2022-2023 | Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.67 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $24.48 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.39 | 2022 | |
| Noven Therapeutics, LLC | $18.38 | 2024 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.78 | 2022 | |
| Bausch Health US, LLC | $15.55 | 2023 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $15.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Fellingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.